Reshape Lifesciences (NASDAQ: RSLS) is one of 80 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its rivals? We will compare Reshape Lifesciences to similar businesses based on the strength of its valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.
Earnings and Valuation
This table compares Reshape Lifesciences and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Reshape Lifesciences||$790,000.00||-$23.36 million||-0.25|
|Reshape Lifesciences Competitors||$2.14 billion||$234.27 million||-84.39|
Reshape Lifesciences’ rivals have higher revenue and earnings than Reshape Lifesciences. Reshape Lifesciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
0.8% of Reshape Lifesciences shares are owned by institutional investors. Comparatively, 51.7% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 26.4% of Reshape Lifesciences shares are owned by company insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Reshape Lifesciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Reshape Lifesciences Competitors||-315.68%||-23.48%||-9.77%|
Risk & Volatility
Reshape Lifesciences has a beta of 2.97, meaning that its share price is 197% more volatile than the S&P 500. Comparatively, Reshape Lifesciences’ rivals have a beta of 1.17, meaning that their average share price is 17% more volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Reshape Lifesciences and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Reshape Lifesciences Competitors||283||1930||3429||109||2.58|
Reshape Lifesciences currently has a consensus target price of $11.03, indicating a potential upside of 645.27%. As a group, “Advanced Medical Equipment & Technology” companies have a potential upside of 1.24%. Given Reshape Lifesciences’ stronger consensus rating and higher probable upside, analysts clearly believe Reshape Lifesciences is more favorable than its rivals.
Reshape Lifesciences rivals beat Reshape Lifesciences on 7 of the 13 factors compared.
Reshape Lifesciences Company Profile
ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.
Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.